On September 9, 2020 The National Institute for Heath and Care Excellence (NICE) reported that it has turned down NHS funding of Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults (Press release, Celgene, SEP 9, 2020, View Source [SID1234564993]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
There is currently no maintenance treatment for newly diagnosed multiple myeloma in people who have had an autologous stem cell transplant; the condition is usually monitored until it gets worse.
Clinical trial results show that, compared with monitoring alone, Revlimid increases how long people live and also extends the time before the condition gets worse.
However, NICE has concluded in preliminary guidelines that cost-effectiveness estimates for the drug in this setting "are uncertain".
"This is because of limitations in the cost-effectiveness model, and because the model might not reflect what happens in the NHS in England," it said.
Therefore, Revlimid could not be considered value for money for the NHS when used for this indication, it noted.